Yervoy delivers a surprise in liver cancer
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
Astra’s radiopharma Fusion
AstraZeneca's quiet, cautious work is followed by a $2bn takeover.
AACR 2024 preview – clinical highlights and lowlights
The 2024 AACR abstract title drop features several noteworthy clinical studies.
Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
Astra takes Steap2 into human trials
First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.
The new normal in US oncology approvals
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
